Kidney cancer is not rare. It is one of the more common cancers in the United States, with roughly 1.8 percent of all people receiving a diagnosis at some point in their lifetime. The National Cancer Institute defines rare cancers as those affecting fewer than 40,000 people per year, and kidney cancer exceeds that threshold by a wide margin. That said, some specific subtypes of kidney cancer are genuinely rare, which is where the confusion often comes from.
How Common Kidney Cancer Actually Is
Globally, kidney cancer incidence more than doubled between 1990 and 2021, rising from about 160,000 new cases per year to 390,000. The median age at diagnosis is 65, and the disease affects men roughly twice as often as women. In the United States, age-adjusted incidence rates have recently begun to level off or slightly decline, but kidney cancer remains firmly in the top ten most diagnosed cancers.
One major reason the numbers have climbed over the past few decades is better imaging. About 50 percent of all kidney tumors are now discovered incidentally, meaning they show up on a CT scan or MRI ordered for something completely unrelated. For small tumors under 4 centimeters, that figure rises to 60 to 70 percent. More scanning means more detection, especially of early-stage tumors that might never have been found in previous decades.
Which Subtypes Are Rare
Kidney cancer is an umbrella term covering several distinct tumor types, and while the disease overall is common, certain subtypes are not. The most frequent form, clear cell renal cell carcinoma, accounts for about 75 percent of all cases. Papillary renal cell carcinoma makes up roughly 10 percent, and chromophobe renal cell carcinoma around 5 percent. Together these three subtypes represent more than 90 percent of kidney cancers.
The remaining fraction includes genuinely rare tumors. Collecting duct carcinoma (also called Bellini duct carcinoma) and renal medullary carcinoma each account for about 1 percent of cases. Translocation renal cell carcinoma and mucinous tubular spindle cell carcinoma are rarer still. The NCI specifically lists several of these as rare kidney tumors, particularly when they occur in children, teens, and young adults. So if you’ve read that kidney cancer is rare, you may have been reading about one of these uncommon subtypes rather than the disease as a whole.
Kidney Cancer in Children
In children, kidney cancer is a different story. The most common pediatric form, Wilms tumor, occurs at a rate of about 9.7 cases per million children under 15. That qualifies it as rare in absolute terms, even though it is the most common kidney cancer in that age group. Wilms tumor is almost never seen in adults, representing less than 1 percent of all adult kidney tumors. Renal cell carcinoma, the dominant adult form, is extremely uncommon in children.
Survival Rates by Stage
The growing number of incidental discoveries has had a meaningful effect on outcomes. Because so many kidney cancers are now caught before they cause symptoms, a larger share are diagnosed at an early, localized stage. The five-year relative survival rate for localized kidney cancer is 93 percent. When the cancer has spread to nearby lymph nodes or tissues (regional stage), that drops to 76 percent. For distant-stage disease that has spread to other organs, the five-year survival rate is 19 percent.
These numbers, based on people diagnosed between 2015 and 2021, reflect real improvements over earlier decades. Earlier detection through routine imaging is a key driver, but advances in surgical techniques and targeted treatments have also contributed, particularly for regional-stage disease.
Why the “Rare” Label Causes Confusion
The disconnect comes down to how the word “rare” gets applied. Kidney cancer as a category is common. But medical literature, clinical trials, and advocacy organizations often focus on individual subtypes, many of which are rare by any standard. A patient diagnosed with collecting duct carcinoma or translocation renal cell carcinoma faces the challenges typical of rare diseases: fewer specialists, fewer clinical trials, and less established treatment pathways. Someone with clear cell renal cell carcinoma, on the other hand, has a well-studied disease with a broad range of treatment options.
If you or someone you know has been diagnosed, the subtype matters more than the overall category. Knowing whether the specific tumor is common or rare can help set expectations for the treatment landscape and the volume of research available.